LINC01232 and neoplasm: LINC01232 binds to E2F2 to enter the nucleus and collaboratively upregulates NBR1, mediating the degradation of histocompatibility complex Class I molecules (MHC-I) by autophagy lysosomes, enabling CD8+ T cells to effectively recognize tumor-specific antigens and thereby evade immune surveillance.